SLXN
Silexion Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.35
+0.06%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$1.96M
MomentumView details →
1D Return
+0.06%
YTD Return
−98.13%
RSI (14)
20.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$1.96M
RSI (14)
20.3
MomentumView details →
1D Return
+0.06%
YTD Return
−98.13%
SummaryUpdated Jun 1, 2026
Silexion Therapeutics LTD (NASDAQ:SLXN) is an Israeli biopharmaceutical company founded in 2008 and headquartered in Jerusalem. The company went public in August 2024 and specializes in developing RNA interference (RNAi)-based cancer treatments for solid tumors using its proprietary LODER delivery platform. As a clinical-stage biotechnology company, Silexion focuses on creating targeted therapies that can be delivered directly to tumor sites, representing an innovative approach to cancer treatment that aims to overcome limitations of traditional systemic therapies.
Similar companies
Latest newsMore news →
Silexion Therapeutics Corp received a notice from Nasdaq on August 18, 2026, stating it no longer complies with the minimum shareholders' equity requirement under Rule 5550(b)(1), and the company plans to appeal before the Nasdaq Hearings Panel.15d agoSilexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares and series E warrants at a combined price of $0.65 per share, expected to close on August 13, 2026.24d ago